We have updated our Privacy Policy and Terms of Use for Eurasia Group and its affiliates, including GZERO Media, to clarify the types of data we collect, how we collect it, how we use data and with whom we share data. By using our website you consent to our Terms and Conditions and Privacy Policy, including the transfer of your personal data to the United States from your country of residence, and our use of cookies described in our Cookie Policy.
President Joe Biden waits on stage during a White House event announcing moves to lower the prices of ten widely-used prescription drugs
The Biden administration this week selected the first 10 drugs that will be subject to price negotiations between the US government and pharma companies.
The move, part of the White House’s signature Inflation Reduction Act, aims to bring down the sky-high prices that people on Medicare, the government’s medical insurance program for people 65 and older, pay for many lifesaving drugs. By wrangling down drug prices, Biden also hopes to shore up the financial solvency of Medicare itself. The new, lower drug prices are supposed to take effect by 2026.
Bringing down drug prices is hugely popular with Americans of both parties, particularly older folks. Americans, on average, pay more than twice as much for medicines as people in other advanced economies, and more than three times as much for brand-name drugs, according to a 2021 Rand Corporation study. Nearly 30% of Americans have trouble paying for their meds, a recent Kaiser Family Foundation study found.
But Big Pharma isn’t happy about it. Drug manufacturers say that artificially suppressing prices for cutting-edge medications will rob them of the money they need to invest in developing new cures. Several large companies have already sued the Biden administration, arguing that the move violates constitutional prohibitions on the government messing with people’s private property.
Don’t be surprised if this one goes all the way to the Supreme Court.